DSFIRN Stock Chart & Stats
$1301.79
$0.00(0.00%)
At close: 4:00 PM EDT
$1301.79
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,301.79 - $2,528.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$446.69B
Enterprise Value$25.37K
Total Cash (Recent Filing)$2.31B
Total Debt (Recent Filing)$6.76B
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Feb 18, 2027EPS Estimate
31.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.82
Shares Outstanding253,626,950
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.98
Price to Sales (P/S)1.97
P/FCF Ratio28.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,721.83Price Target Upside32.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)71.3
Revenue Forecast (FY)$184.54B
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & Gross MarginDouble-digit TTM revenue growth (+17.4%) alongside a gross margin improvement (~41.9%) indicates strengthening demand and improved pricing/mix. That supports more durable top-line momentum and margin expansion prospects, reinforcing medium-term cash generation and funding for R&D and customer programs.
Strong Cash GenerationRobust operating cash flow (~1.82B TTM) and positive free cash flow (~764.5M) show the business converts sales into cash despite accounting losses. Durable cash generation provides financial flexibility to fund capex and innovation, reduce leverage, support M&A or sustain shareholder returns across several quarters.
Sticky B2B Model & ServicesDSM-Firmenich’s B2B ingredient model uses multi-year contracts and embedded application, formulation, sensory and regulatory services. These capabilities raise switching costs and deepen client ties, supporting recurring revenue, product embedding and resilience versus commoditization over the medium term.
Bears Say
Net Losses And Negative ROEMeaningfully negative net margins (TTM -13.4%) and negative ROE (~-5.9%) show the company is not translating sales into shareholder earnings. Persistent losses erode capital returns, limit the ability to fund growth internally, and raise the risk that equity value creation remains impaired over coming quarters.
Rising LeverageLeverage has risen (debt/equity ~0.38 TTM vs ~0.21–0.24 earlier), reflecting increased borrowing. Rising leverage reduces balance-sheet flexibility, magnifies stress if cash flows weaken, and can limit strategic investments, M&A or dividend policy unless earnings and cash generation improve sustainably.
Volatile & Softened ProfitabilityOperating profitability has softened (EBIT margin ~5.5% TTM vs ~7.9% in 2025) and earnings have been volatile year-to-year. This margin pressure suggests sensitivity to raw-material, energy or mix swings, undermining predictability of profits and complicating long-term planning for reinvestment and returns.
DSM-Firmenich AG News
DSFIRN FAQ
What was DSM-Firmenich AG’s price range in the past 12 months?
DSM-Firmenich AG lowest stock price was $1301.79 and its highest was $2528.25 in the past 12 months.
What is DSM-Firmenich AG’s market cap?
DSM-Firmenich AG’s market cap is $446.69B.
When is DSM-Firmenich AG’s upcoming earnings report date?
DSM-Firmenich AG’s upcoming earnings report date is Feb 18, 2027 which is in 199 days.
How were DSM-Firmenich AG’s earnings last quarter?
DSM-Firmenich AG released its earnings results on Jul 30, 2026. The company reported $17.612 earnings per share for the quarter, missing the consensus estimate of $17.872 by -$0.26.
Is DSM-Firmenich AG overvalued?
According to Wall Street analysts DSM-Firmenich AG’s price is currently Undervalued.
Does DSM-Firmenich AG pay dividends?
DSM-Firmenich AG does not currently pay dividends.
What is DSM-Firmenich AG’s EPS estimate?
DSM-Firmenich AG’s EPS estimate is 31.22.
How many shares outstanding does DSM-Firmenich AG have?
DSM-Firmenich AG has 253,626,950 shares outstanding.
What happened to DSM-Firmenich AG’s price movement after its last earnings report?
DSM-Firmenich AG reported an EPS of $17.612 in its last earnings report, missing expectations of $17.872. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of DSM-Firmenich AG?
Currently, no hedge funds are holding shares in MX:DSFIRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. The Animal Nutrition & Health segment offers animal proteins, vitamins, performance solutions, and data-driven precision services. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.
DSFIRN Stock 12 Month Forecast
Average Price Target
$1,721.83
▲(32.27% Upside)